I
Ilise Lombardo
Researcher at Pfizer
Publications - 18
Citations - 758
Ilise Lombardo is an academic researcher from Pfizer. The author has contributed to research in topics: Ziprasidone & Atypical antipsychotic. The author has an hindex of 12, co-authored 18 publications receiving 664 citations. Previous affiliations of Ilise Lombardo include AMAG Pharmaceuticals.
Papers
More filters
Journal ArticleDOI
Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis
Teresa Coelho,Giampaolo Merlini,Christine Bulawa,James Fleming,Daniel P. Judge,Jeffery W. Kelly,Mathew S. Maurer,Violaine Planté-Bordeneuve,Richard Labaudinière,Rajiv Mundayat,Steve Riley,Ilise Lombardo,Pedro E. Huertas +12 more
TL;DR: Tafamidis meglumine is a rationally designed, non-NSAID benzoxazole derivative that binds with high affinity and selectivity to TTR and kinetically stabilizes the tetramer, slowing monomer formation, misfolding, and amyloidogenesis.
Journal ArticleDOI
Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia.
Richard S.E. Keefe,Herbert A Meltzer,Nancy Dgetluck,Maria Gawryl,Gerhard Koenig,Hans J Moebius,Ilise Lombardo,Dana Hilt +7 more
TL;DR: Overall, encenicline was generally well tolerated and demonstrated clinically meaningful improvements in cognition and function in patients with schizophrenia.
Journal ArticleDOI
Tafamidis in Transthyretin Amyloid Cardiomyopathy: Effects on Transthyretin Stabilization and Clinical Outcomes
Mathew S. Maurer,Donna R. Grogan,Daniel P. Judge,Rajiv Mundayat,Jeff Packman,Ilise Lombardo,Arshed A. Quyyumi,Janske Aarts,Rodney H. Falk +8 more
TL;DR: In this article, a phase 2 open-label trial evaluated the stabilization of TTR tetramers using 20 mg of tafamidis daily at week 6 (primary end point), month 6, and month 12.
Journal ArticleDOI
Findings of a U.S. national cardiometabolic screening program among 10,084 psychiatric outpatients.
Christoph U. Correll,Benjamin G. Druss,Ilise Lombardo,Cedric O'Gorman,James Harnett,Kafi N. Sanders,Jose Alvir,Brian J. Cuffel +7 more
TL;DR: The prevalence of metabolic syndrome and cardiometabolic risk factors, such as overweight, hypertension, dyslipidemia, and glucose abnormalities, was substantial and frequently untreated in this U.S. national mental health clinic screening program.
Journal ArticleDOI
Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome?
TL;DR: Two randomized, double-blind, placebo-controlled, 6-week studies comparing ziprasidone versus placebo for treatment of bipolar depression (BPD) failed to meet their primary study objectives, indicating that either ziprasidsone is ineffective in the treatment of BPD or the study failed.